title: Potential benefits of quetiapine in the treatment of substance dependence disorders.
abstract: OBJECTIVE
  Some antipsychotic medications prescribed for the treatment of psychoses, mood disorders or post-traumatic stress disorder in patients with coexisting substance dependence disorders (SDD) have reduced substance dependence. We studied the potential benefits of quetiapine in the treatment of SDD.
  
  
  METHODS
  We conducted a retrospective chart review of data for 9 patients who were admitted to a 28-day residential rehabilitation program designed for individuals with SDD during a 3-month period from January 2003 through March 2003 and treated with quetiapine for nonpsychotic anxiety. These patients also met the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, criteria for alcohol, cocaine and/or methamphetamine dependence and substance-induced anxiety disorder. The patients were assessed using the Hamilton-D Rating Scale for Depression (Ham-D), a 10-point Likert scale to measure alcohol or drug cravings, and random Breathalyzer and urine drug screens.
  
  
  RESULTS
  Quetiapine was generally well tolerated. Only 1 of the 9 patients stopped taking the medication because of increased anxiety. Other patients reported improvement in sleep and anxiety. The mean decrease in Ham-D score at discharge for the responders was 18.5 (p < 0.005). The biggest decreases on the Ham-D occurred on the subscales of insomnia, agitation, somatic anxiety, psychologic anxiety, hypochondriasis and obsessional symptoms. The mean decrease in the Likert 10-point craving scale was 5.9 for the responders (p < 0.005). These patients' periodic Breathalyzer and urine test results suggested that they remained abstinent from alcohol and other drug use.
  
  
  CONCLUSIONS
  Quetiapine was beneficial in the treatment of SDD in patients with nonpsychotic anxiety.
authors.affiliation: Department of Psychiatry, Creighton University School of Medicine and Omaha VA Medical Center, Omaha, NE 68131, USA. syed.sattar@med.va.gov
authors.forename: S Pirzada
authors.initials: SP
authors.lastname: Sattar
authors.forename: Subhash C
authors.initials: SC
authors.lastname: Bhatia
authors.forename: Frederick
authors.initials: F
authors.lastname: Petty
mesh_terms: D000328:Adult; D000437:Alcoholism / Q000534:rehabilitation*; D019969:Amphetamine-Related Disorders / Q000534:rehabilitation*; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000139:chemically induced / Q000534:rehabilitation; D019970:Cocaine-Related Disorders / Q000534:rehabilitation*; D015897:Comorbidity; D003987:Dibenzothiazepines / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008694:Methamphetamine; D008875:Middle Aged; D009329:Nebraska; D010343:Patient Admission; D000069348:Quetiapine Fumarate; D012189:Retrospective Studies; D015813:Substance Abuse Detection; D016320:Substance Abuse Treatment Centers; D016896:Treatment Outcome
chemical_list: D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D000069348:Quetiapine Fumarate; D008694:Methamphetamine